189 related articles for article (PubMed ID: 22377923)
21. The pathophysiology of acute graft-versus-host disease.
Jaksch M; Mattsson J
Scand J Immunol; 2005 May; 61(5):398-409. PubMed ID: 15882431
[TBL] [Abstract][Full Text] [Related]
22. The thymus in GVHD pathophysiology.
Krenger W; Holländer GA
Best Pract Res Clin Haematol; 2008 Jun; 21(2):119-28. PubMed ID: 18503980
[TBL] [Abstract][Full Text] [Related]
23. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of cytokines during graft-versus-host disease.
Krenger W; Ferrara JL
J Hematother; 1996 Feb; 5(1):3-14. PubMed ID: 8646479
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
27. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
28. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients.
Lo JW; Leung AY; Huang XR; Lie AK; Metz C; Bucala R; Liang R; Lan HY
Bone Marrow Transplant; 2002 Sep; 30(6):375-80. PubMed ID: 12235522
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
30. Early-onset lichenoid graft-vs.-host disease: a unique variant of acute graft-vs.-host disease occurring in peripheral blood stem cell transplant recipients.
Magro CM; Kerns MJ; Votava H; Vasil KE; Dyrsen ME; Morrison CD
J Cutan Pathol; 2010 May; 37(5):549-58. PubMed ID: 19843195
[TBL] [Abstract][Full Text] [Related]
31. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease.
Sackstein R
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):2-8. PubMed ID: 16399577
[TBL] [Abstract][Full Text] [Related]
32. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
33. Eruption of lymphocyte recovery or autologous graft-versus-host disease?
Nellen RG; van Marion AM; Frank J; Poblete-Gutiérrez P; Steijlen PM
Int J Dermatol; 2008 Nov; 47 Suppl 1():32-4. PubMed ID: 18986483
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous graft-versus-host disease: a guide for the dermatologist.
Häusermann P; Walter RB; Halter J; Biedermann BC; Tichelli A; Itin P; Gratwohl A
Dermatology; 2008; 216(4):287-304. PubMed ID: 18230976
[TBL] [Abstract][Full Text] [Related]
35. Acute graft-versus-host disease in children.
Jacobsohn DA
Bone Marrow Transplant; 2008 Jan; 41(2):215-21. PubMed ID: 17934526
[TBL] [Abstract][Full Text] [Related]
36. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of pDCs, mDCs, γδT cells and regulatory T cells in association with graft versus host disease after hematopoietic stem cell transplantation.
Watanabe N; Narita M; Furukawa T; Nakamura T; Yamahira A; Masuko M; Toba K; Fuse I; Aizawa Y; Takahashi M
Int J Lab Hematol; 2011 Aug; 33(4):378-90. PubMed ID: 21692996
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
[TBL] [Abstract][Full Text] [Related]
39. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
[TBL] [Abstract][Full Text] [Related]
40. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
